Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Amyloid imaging plays an important role in the research and diagnosis of dementing disorders. Substantial variation in quantitative methods to measure brain amyloid burden exists in the field. The aim of this work is to investigate the impact of methodological variations to the quantification of amyloid burden using data from the Dominantly Inherited Alzheimer's Network (DIAN), an autosomal dominant Alzheimer's disease population. Cross-sectional and longitudinal [11C]-Pittsburgh Compound B (PiB) PET imaging data from the DIAN study were analyzed. Four candidate reference regions were investigated for estimation of brain amyloid burden. A regional spread function based technique was also investigated for the correction of partial volume effects. Cerebellar cortex, brain-stem, and white matter regions all had stable tracer retention during the course of disease. Partial volume correction consistently improves sensitivity to group differences and longitudinal changes over time. White matter referencing improved statistical power in the detecting longitudinal changes in relative tracer retention; however, the reason for this improvement is unclear and requires further investigation. Full dynamic acquisition and kinetic modeling improved statistical power although it may add cost and time. Several technical variations to amyloid burden quantification were examined in this study. Partial volume correction emerged as the strategy that most consistently improved statistical power for the detection of both longitudinal changes and across-group differences. For the autosomal dominant Alzheimer's disease population with PiB imaging, utilizing brainstem as a reference region with partial volume correction may be optimal for current interventional trials. Further investigation of technical issues in quantitative amyloid imaging in different study populations using different amyloid imaging tracers is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Su et al. 42,49 has demonstrated that the RSF technique was able to improve PET quantification and achieve better sensitivity to longitudinal changes in amyloid burden.”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · cited 2×
“In comparison, in this current study in the DIAN cohort using PiB as the tracer, we observed a substantially larger annual rate of 0.02±0.03 in SUVR in a cohort that is a mixture of MCI (CDR = 0.5) and asymptomatic participants using similar reference region.”
MethodInfluentialSelf-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundSimplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden [11,22].”
MethodPartial-Volume Effect in PET Tumor Imaging
Soret, M., Bacharach, S. L., & Buvat, I. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035774 · Cited by 1,549 · cited 1×
“PET imaging based measurement is subjected to partial volume effects, because of the low spatial resolution [19].”
BackgroundDistribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 2×
“Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden [11,22].”
MethodLogan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479 · cited 1×
“Logan graphical analysis [35] was then applied to obtain regional VT, which is a measurement of absolute tracer binding.”
MethodAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 2×
“AD pathology begins to accumulate at least 10 to 20 years before clinical symptoms appear [1,3,4], and there is a growing consensus that effective treatment of AD will require early intervention [5,6].”
BackgroundSelf-citation[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 4×
“Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden [11,22].”
MethodInfluentialSelf-citation2014 Alzheimer's disease facts and figures
Alzheimer's Association (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.001 · Cited by 1,020
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760 · cited 1×
“The amyloid cascade is the primary target of the largest ongoing clinical trials [7], including DIAN-TU (DIAN Trial Unit) [8], A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) [9], and API (Alzheimer’s Prevention Initiative) [10] in preclinical population.”
BackgroundSelf-citationSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · cited 1×
“The amyloid cascade is the primary target of the largest ongoing clinical trials [7], including DIAN-TU (DIAN Trial Unit) [8], A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer ’ s Disease) [9], and API (Alzheimer ’ s Prevention Initiative) [10] in preclinical population.”
BackgroundLopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 543
Self-citationFully 3-D PET reconstruction with system matrix derived from point source measurements
Panin, V. Y., Kehren, F., Michel, C., & Casey, M. (2006) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2006.876171 · Cited by 536
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391 · cited 4×
“value-ratio (SUVR) [4,16,17].”
BackgroundMethodInfluentialSelf-citationJoshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.090340 · Cited by 391 · cited 1×
“While MR data is generally available for most of the ongoing neuroimaging studies, quantification methods that does not require MR [37–39] have their advantages and warrant further investigation.”
MethodClinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 373
Landau, S. M., Fero, A., Baker, S. L., Koeppe, R., Mintun, M., Chen, K., Reiman, E. M., & Jagust, W. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148981 · Cited by 364
Self-citationIs increased blinking a form of blepharospasm?
(2013) · CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) · doi:10.1212/wnl · Cited by 355
Alzheimer's Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Reiman, E. M., Langbaum, J. B. S., Fleisher, A. S., Caselli, R. J., Chen, K., Ayutyanont, N., Quiroz, Y. T., Kosik, K. S., Lopera, F., & Tariot, P. N. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-0059 · Cited by 339 · cited 1×
“The amyloid cascade is the primary target of the largest ongoing clinical trials [7], including DIAN-TU (DIAN Trial Unit) [8], A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease) [9], and API (Alzheimer’s Prevention Initiative) [10] in preclinical population.”
BackgroundSelf-citationThomas, B. A., Erlandsson, K., Modat, M., Thurfjell, L., Vandenberghe, R., Ourselin, S., & Hutton, B. F. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1745-9 · Cited by 316 · cited 2×
“[21] reported improved quantitative accuracy using a region-based voxel-wise partial volume correction (PVC) method.”
MethodResultComparative evaluation of MR-based partial-volume correction schemes for PET.
MELTZER, C. C., Kinahan, P. E., Greer, P. J., Nichols, T. E., Comtat, C., Cantwell, M. N., Lin, M., & Price, J. C. (1999) · PubMed · Cited by 254
Partial volume correction in quantitative amyloid imaging
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Marcus, D. S., Ances, B. M., Bateman, R. J., Cairns, N. J., Aldea, P., Cash, L., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.058 · Cited by 247 · cited 8×
“Correction of partial volume effects represents another area of active investigation [18].”
BackgroundMethodResultInfluentialSelf-citationQuantitative Analysis of PiB-PET with FreeSurfer ROIs
Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246 · cited 4×
“A PET Unified Pipeline (PUP) (https://github.com/ysu001/PUP) was used for automated PET data analysis [12,18].”
MethodInfluentialSelf-citationMorris, J. C., Aisen, P. S., Bateman, R. J., Benzinger, T. L., Cairns, N. J., Fagan, A. M., Ghetti, B., Goate, A. M., Holtzman, D. M., Klunk, W. E., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.93 · Cited by 208 · cited 8×
“In comparison, in this current study in the DIAN cohort using PiB as the tracer, we observed a substantially larger annual rate of 0.02±0.03 in SUVR in a cohort that is a mixture of MCI (CDR = 0.5) and asymptomatic participants using similar reference region.”
BackgroundInfluentialSelf-citationApolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred
Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194 · cited 1×
“Each participant’s apolipoprotein E (APOE) genotype was determined using previously described methods [32].”
MethodMann, D. M. A., Pickering-Brown, S. M., Takeuchi, A., & Iwatsubo, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64688-3 · Cited by 182 · cited 1×
“However, the observation of amyloid deposition in the cerebellar cortex of familial AD cases [13,14] had led to the identification and validation of pons as an alternative reference region [15].”
BackgroundReport of the task force on designing clinical trials in early (predementia) AD
Aisen, P. S., Andrieu, S., Sampaio, C., Carrillo, M., Khachaturian, Z. S., Dubois, B., Feldman, H. H., Petersen, R. C., Siemers, E., Doody, R. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318207b1b9 · Cited by 172 · cited 2×
“AD pathology begins to accumulate at least 10 to 20 years before clinical symptoms appear [1,3,4], and there is a growing consensus that effective treatment of AD will require early intervention [5,6].”
BackgroundChen, K., Roontiva, A., Thiyyagura, P., Lee, W., Liu, X., Ayutyanont, N., Protas, H. D., Luo, J., Bauer, R. J., III, Reschke, C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.149732 · Cited by 172
Self-citationLongitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations
van Berckel, B. N. M., Ossenkoppele, R., Tolboom, N., Yaqub, M., Foster-Dingley, J. C., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & Boellaard, R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.113654 · Cited by 162 · cited 2×
“As previously reported [36], SUVR analysis is more sensitive to the choice of time window used for quantification.”
MethodResultTohka, J., & Reilhac, A. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.10.038 · Cited by 160
Brendel, M., Högenauer, M., Delker, A., Sauerbeck, J., Bartenstein, P., Seibyl, J. P., & Rominger, A. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.11.055 · Cited by 140 · cited 7×
“These criteria include low inter-subject variability in reference regions [15,22], strong group differences between control subjects and AD patients [15,16,22], and, in longitudinal studies, strong longitudinal changes [16,17,25].”
BackgroundMethodResultInfluentialPreclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial
Mills, S. M., Mallmann, J., Santacruz, A. M., Fuqua, A., Carril, M., Aisen, P. S., Althage, M. C., Belyew, S., Benzinger, T. L., Brooks, W. S., et al. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.017 · Cited by 139 · cited 2×
“The amyloid cascade is the primary target of the largest ongoing clinical trials [7], including DIAN-TU (DIAN Trial Unit) [8], A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer ’ s Disease) [9], and API (Alzheimer ’ s Prevention Initiative) [10] in preclinical population.”
BackgroundSelf-citationRousset, O. G., Collins, D. L., Rahmim, A., & Wong, D. F. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048330 · Cited by 106 · cited 1×
“PVC was also performed using a regional spread function (RSF) technique implemented in PUP [18], which is also known as the geometric transfer matrix (GTM) technique [33].”
MethodFamilial and sporadic Alzheimer's disease: Neuropathology cannot exclude a final common pathway
Lippa, C. F., Saunders, A. M., Smith, T. W., Swearer, J. M., Drachman, D. A., Ghetti, B., Nee, L., Pulaski-Salo, D., Dickson, D., Robitaille, Y., et al. (1996) · Neurology · doi:10.1212/wnl.46.2.406 · Cited by 97 · cited 1×
“However, the observation of amyloid deposition in the cerebellar cortex of familial AD cases [13,14] had led to the identification and validation of pons as an alternative reference region [15].”
BackgroundSelf-citationAlzheimer's disease therapeutic research: the path forward
Aisen, P. S. S. (2009) · Alzheimer s Research & Therapy · doi:10.1186/alzrt2 · Cited by 62 · cited 2×
“AD pathology begins to accumulate at least 10 to 20 years before clinical symptoms appear [1,3,4], and there is a growing consensus that effective treatment of AD will require early intervention [5,6].”
BackgroundSu, Y., Arbeláez, A. M., Benzinger, T. L. S., Snyder, A. Z., Vlassenko, A. G., Mintun, M. A., & Raichle, M. E. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.143 · Cited by 47 · cited 1×
“An IDAIF was obtained using a recently developed technique by combined analysis of TOF-MRA, T1-weighted MR, and dynamic PET imaging data [30,34].”
MethodSelf-citationCan target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?
Edison, P., Hinz, R., Ramlackhansingh, A. F., Thomas, J., Gelosa, G., Archer, H. A., Turkheimer, F., & Brooks, D. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.099 · Cited by 42 · cited 4×
“However, the observation of amyloid deposition in the cerebellar cortex of familial AD cases [13,14] had led to the identification and validation of pons as an alternative reference region [15].”
BackgroundInfluentialQuantitative Amyloid Imaging Using Image-Derived Arterial Input Function
Su, Y., Blazey, T. M., Snyder, A. Z., Raichle, M. E., Hornbeck, R. C., Aldea, P., Morris, J. C., & Benzinger, T. L. S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122920 · Cited by 37 · cited 3×
“In addition, 42 participants (21 mutation carriers) from the WU site who had time-of-flight (TOF) MR angiography (MRA) scans and 70-min dynamic PiB PET scans were included for absolute quantification (AQ) of PiB binding using an image-derived arterial input function (IDAIF) technique [30].”
MethodSelf-citationAutomated 11C-PiB Standardized Uptake Value Ratio
Raniga, P., Bourgeat, P., Fripp, J., Acosta, O., Villemagne, V. L., Rowe, C. C., Masters, C. L., Jones, G. R., O'Keefe, G. J., Salvado, O., et al. (2008) · Academic Radiology · doi:10.1016/j.acra.2008.07.006 · Cited by 28 · cited 1×
“While MR data is generally available for most of the ongoing neuroimaging studies, quantification methods that does not require MR [37–39] have their advantages and warrant further investigation.”
MethodSelf-citationDeformation field correction for spatial normalization of PET images
Bilgel, M., Carass, A., Resnick, S. M., Wong, D. F., & Prince, J. L. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.06.063 · Cited by 8 · cited 1×
“While MR data is generally available for most of the ongoing neuroimaging studies, quantification methods that does not require MR [37–39] have their advantages and warrant further investigation.”
MethodSimplified quantification of PIB amyloid imaging PET studies
Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., DeKosky, S. T., & Price, J. C. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9591524.0589 · Cited by 5
Self-citation(2014) · Institutional Repository University of Antioquia (University of Antioquia) · doi:10.1371/journal.pone
Cited by
LaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
“Su et al. 42,49 has demonstrated that the RSF technique was able to improve PET quantification and achieve better sensitivity to longitudinal changes in amyloid burden.”
Self-citationLa Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Self-citationLongitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314
“We have previously demonstrated that for PiB-PET there were no significant differences in results when using a cerebellar, pons, or white matter reference.(21)”
ResultSelf-citationGonzalez-Escamilla, G., Lange, C., Teipel, S., Buchert, R., & Grothe, M. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.077 · Cited by 186
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
Rowe, C. C., Jones, G., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 140
Self-citation
Metadata
- Authors
- Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., Cash, L. A., Koeppe, R. A., Klunk, W. E., Galasko, D., Brickman, A. M., McDade, E., Ringman, J. M., Thompson, P. M., Saykin, A. J., Ghetti, B., Sperling, R. A., Johnson, K. A., Salloway, S. P., Schofield, P. R., Masters, C. L., Villemagne, V. L., Fox, N. C., Förster, S., Chen, K., Reiman, E. M., Xiong, C., Marcus, D. S., Weiner, M. W., Morris, J. C., Bateman, R. J., Benzinger, T. L. S., & Dominantly Inherited Alzheimer Network
- Affiliations
- Washington University in St. Louis (US)
- University of Michigan (US)
- University of Pittsburgh (US)
- University of California San Diego (US)
- Columbia University (US)
- University of Southern California (US)
- Indiana University Indianapolis (US)
- Harvard University (US)
- Brown University (US)
- UNSW Sydney (AU)
- The University of Melbourne (AU)
- UCL Queen Square Institute of Neurology (GB)
- German Center for Neurodegenerative Diseases (DE)
- Banner Health (US)
- University of California, San Francisco (US)
- Corresponding author
- Su, Yi
- ORCID
- Su, Yi
- Blazey, Tyler M.
- Friedrichsen, Karl
- Wang, Qing
- Hornbeck, Russ C.
- Ances, Beau M.
- Snyder, Abraham Z.
- Koeppe, Robert A.
- Klunk, William E.
- Brickman, Adam M.
- McDade, Eric
- Ringman, John M.
- Thompson, Paul M.
- Saykin, Andrew J.
- Ghetti, Bernardino
- Sperling, Reisa A.
- Johnson, Keith A.
- Salloway, Stephen P.
- Schofield, Peter R.
- Masters, Colin L.
- Villemagne, Victor L.
- Fox, Nick C.
- Förster, Stefan
- Chen, Kewei
- Reiman, Eric M.
- Xiong, Chengjie
- Marcus, Daniel S.
- Weiner, Michael W.
- Morris, John C.
- Bateman, Randall J.
- Benzinger, Tammie L. S.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-24
- Volume
- 11
- Issue
- 3
- Pages
- e0152082
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4807073
- OpenAlex
- W2316313792
- Semantic Scholar
- 17effc405abab01da955a23a9c372449e994197a
- Cited by
- 56
- References
- 45
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 2 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 4 · 2016: 6
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-09-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (P01AG026276)
- Institute of Clinical and Translational Sciences (UL1TR000448)
- Georgia Clinical and Translational Science Alliance (UL1TR000448)
- National Institute for Health and Care Research (NF-SI-0513-10134)
- National Institutes of Health (UL1TR000448)
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (U19AG032438, P50AG005681, P30NS048056, P01AG003991, P01AG026276)
- National Institute on Aging (P30AG053760, P50AG005131, UF1AG032438, P50AG005681, P50AG005142, P01AG003991, U19AG032438, P01AG026276)
- National Institute of Neurological Disorders and Stroke (P01NS080675, P30NS048056)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- amyloid imaging, autosomal dominant Alzheimer's disease, 11C-Pittsburgh compound B, PiB PET, partial volume correction, reference region, spread function, kinetic modeling
- MeSH terms
- Adult, Alzheimer Disease, Amyloid, Brain, Carbon Isotopes, Cross-Sectional Studies, DNA Mutational Analysis, Family Health, Female, Genes, Dominant, Heterozygote, Humans, Image Processing, Computer-Assisted, Longitudinal Studies, Male, Middle Aged, Mutation, Reference Values, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
